Evidence map›Paper›PMID 39998679›Full record

ArticleCancer immunology, immunotherapy : CII2025

Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non-small cell lung cancer based on real-world data.

Ana D Ramos-Guerra, Benito Farina, Jaime Rubio Pérez, Anna Vilalta-Lacarra, Jon Zugazagoitia, Germán Peces-Barba, Luis M Seijo, Luis Paz-Ares, Ignacio Gil-Bazo, Manuel Dómine Gómez and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ana D Ramos-GuerraBiomedical Image Technologies, Escuela Técnica Superior de Ingenieros de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain. ana.ramos.guerra@upm.es.
Benito FarinaBiomedical Image Technologies, Escuela Técnica Superior de Ingenieros de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain.
Jaime Rubio PérezHospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.
Anna Vilalta-LacarraDepartment of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Jon ZugazagoitiaCentro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Madrid, Spain.
Germán Peces-BarbaHospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.
Luis M SeijoDepartment of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Luis Paz-AresCentro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Madrid, Spain.
Ignacio Gil-BazoHospital Universitario 12 de Octubre, Madrid, Spain.
Manuel Dómine GómezHospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.
María J Ledesma-CarbayoBiomedical Image Technologies, Escuela Técnica Superior de Ingenieros de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain. mj.ledesma@upm.es.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Agencia Estatal de Investigación PDC2022-133865-I00Instituto de Salud Carlos III PMP21/00107NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The identification of non-small cell lung cancer (NSCLC) patients who will benefit from immunotherapy remains a clinical challenge. Monitoring real-world data (RWD) in the first cycles of therapy may provide a more accurate representation of response patterns in a real-world setting. We propose a multivariate Bayesian joint model using generalized linear mixed effects, trained and validated on RWD from 424 advanced NSCLC patients retrospectively collected from three clinical centers. Center1 was used as training (

Indexed as

Carcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsAdultAgedBayes TheoremFemaleHumansMaleMiddle AgedNeutrophilsPrognosisRetrospective StudiesImmunotherapyLongitudinal analysisNon-small-cell lung cancerPeripheral blood biomarkerPrognostic markerReal-world data

Identifiers

PMID39998679
PMCPMC11861465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.